InsiderTrades

Form 4 for ABOS Acumen Pharmaceuticals, Inc.

Accepted 2021-07-08 00:00:00 ET · period of report 2021-07-06 · accession 0001209191-21-046028 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
DI 2021-07-08 2021-07-06 ABOS Hardie Robert D. 10% P - Purchase $16.00 +312.5K 3.35M +10% +$5.00M
DMI 2021-07-08 2021-07-06 ABOS Hardie Robert D. 10% C - Cnv Deriv — +3.61M 658.0K New —
DMI 2021-07-08 2021-07-06 ABOS Hardie Robert D. 10% C - Cnv Deriv $0.00 -3.61M 0 -100% $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2021-07-06 P A 312,500 $16.00 3,352,693 I See footnote — — (F2) The securities are held by The Paul B. Manning Revocable Trust dated May 10, 2000 (the "Trust"). The Reporting Person is the trustee of the Trust and has sole voting and investment power with respect to the shares held by the Trust.
2 Common Common Stock 2021-07-06 C A 2,950,484 — 3,040,193 I See footnote — — (F1) On July 6, 2021, each share of Series A-1 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") converted into Common Stock on a one-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. (F2) The securities are held by The Paul B. Manning Revocable Trust dated May 10, 2000 (the "Trust"). The Reporting Person is the trustee of the Trust and has sole voting and investment power with respect to the shares held by the Trust.
3 Common Common Stock 2021-07-06 C A 657,985 — 657,985 I See footnote — — (F1) On July 6, 2021, each share of Series A-1 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") converted into Common Stock on a one-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. (F3) The shares are held directly by BKB Growth Investments, LLC ("BKB"). The Reporting Person is a co-manager of Tiger Lily Capital, LLC, the manager of BKB, and has shared voting and investment power with respect to the shares held by BKB.
4 Derivative Series B Preferred Stock 2021-07-06 C D 1,315,969 $0.00 0 I See footnote — · — to — 1,315,969 Common Stock (F2) The securities are held by The Paul B. Manning Revocable Trust dated May 10, 2000 (the "Trust"). The Reporting Person is the trustee of the Trust and has sole voting and investment power with respect to the shares held by the Trust. (F1) On July 6, 2021, each share of Series A-1 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") converted into Common Stock on a one-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date.
5 Derivative Series B Preferred Stock 2021-07-06 C D 657,985 $0.00 0 I See footnote — · — to — 657,985 Common Stock (F3) The shares are held directly by BKB Growth Investments, LLC ("BKB"). The Reporting Person is a co-manager of Tiger Lily Capital, LLC, the manager of BKB, and has shared voting and investment power with respect to the shares held by BKB. (F1) On July 6, 2021, each share of Series A-1 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") converted into Common Stock on a one-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date.
6 Derivative Series A-1 Preferred Stock 2021-07-06 C D 1,634,515 $0.00 0 I See footnote — · — to — 1,634,515 Common Stock (F2) The securities are held by The Paul B. Manning Revocable Trust dated May 10, 2000 (the "Trust"). The Reporting Person is the trustee of the Trust and has sole voting and investment power with respect to the shares held by the Trust. (F1) On July 6, 2021, each share of Series A-1 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") converted into Common Stock on a one-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date.